News
ASH data shows extended survival benefit
Klas Palin
2025-12-08
15:36 CET
The company presented additional clinical data at ASH this weekend, further highlighting the efficacy of bexmarilimab (BEX) in hard-to-treat high-risk (HR) MDS patients. The data reinforces our view of BEX as an attractive late-stage asset. We have a fair value of EUR3.1–3.8 per share.
What’s new? The company delivered both an oral and a poster presentation at this year’s American Society of Hematology (ASH) conference in Orlando, Florida, updating the latest clinical data for BEX from the BEXMAB study.
What does it mean? At the oral presentation, Dr Amer Zeidan presented new data from the BEXMAB trial, with a particular focus on hard-to-treat patients harbouring TP53 mutations. Among TP53-mutated patients in the frontline HR-MDS cohort, a complete remission (CR) rate of 70% was reported, with 50% of these patients able to proceed to stem-cell transplantation, a highly promising outcome. In the relapsed and refractory HR-MDS cohort, the median overall survival was updated to 14.5 months, an improvement from the previously reported 13.4 months.
Another important clinical benefit observed in the study was the improvement in transfusion independence (TI). Among treatment-naïve HR-MDS patients who were transfusion-dependent at baseline, 57% achieved TI during the study. Across the overall study population, 23% of transfusion-dependent patients became TI. Achieving TI is a meaningful improvement in patients’ quality of life and is considered a key indicator of therapeutic benefit in MDS.
What do we do? Once again, data from the BEXMAB study underscores the promising profile of BEX and provides further support for advancing the programme to pivotal development. We find the data presented further highlights BEX as an attractive late-stage asset well positioned for partnering, which we continue to view as the key near-term potential share-price catalyst.